Press release
Alnylam and Ionis Pharmaceuticals are the leading companies in the RNA-targeted therapeutics market, which is expected to reach USD 68.5 billion by 2034
RNA-Targeted Therapeutic
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72683
With the global validation of RNA technology following the success of mRNA vaccines, investment and innovation in RNA-targeted therapies such as antisense oligonucleotides (ASOs), RNA interference (RNAi), small activating RNAs, and RNA-binding small molecules have accelerated. Over the next decade, RNA therapeutics are expected to reshape the biopharmaceutical landscape, offering targeted, personalized, and efficient treatment options.
Market Overview
• Market Size 2024: USD 14.7 billion
• Forecast 2034: USD 68.5 billion
• CAGR (2024-2034): 16.4%
Key Highlights:
• Increasing prevalence of rare genetic diseases and cancers fuels demand for RNA-based therapies.
• Expanding clinical pipeline with multiple RNAi and ASO drugs gaining regulatory approval.
• Strong collaborations between biotech start-ups, pharma giants, and academic institutions.
• Advances in RNA delivery platforms, including lipid nanoparticles (LNPs) and conjugated systems, are enhancing therapeutic efficacy.
Although challenges such as delivery barriers, high cost, and safety concerns remain, the outlook for RNA-targeted therapeutics is strongly positive.
Market Segmentation
By Therapeutic Type
• Antisense Oligonucleotides (ASOs)
• RNA Interference (RNAi) Therapeutics
• mRNA-based Therapeutics
• RNA-binding Small Molecules
• Small Activating RNAs (saRNAs)
• Others
By Application
• Oncology
• Genetic Disorders
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Diseases
• Rare & Orphan Diseases
• Others
By Delivery Technology
• Lipid Nanoparticles (LNPs)
• GalNAc Conjugates
• Polymer-based Delivery Systems
• Viral Vectors
• Other Emerging Platforms
By End User
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Hospitals & Specialty Clinics
Segmentation Summary:
RNAi and ASOs dominate the current landscape, with approved therapies for spinal muscular atrophy, amyloidosis, and cholesterol disorders. Oncology and rare diseases are the largest and fastest-growing applications, supported by robust pipelines. LNPs and GalNAc conjugates are the leading delivery systems, enabling precision targeting and improved stability.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72683/rna-targeted-therapeutics-market
Regional Analysis
North America
• Largest market, accounting for over 45% share in 2024.
• Driven by advanced biotech ecosystems, extensive R&D funding, and FDA approvals.
• The U.S. leads with companies like Ionis, Alnylam, and Moderna spearheading RNA innovation.
Europe
• Strong presence with supportive regulatory frameworks and government funding for precision medicine.
• Germany, the UK, and France dominate regional adoption.
• EMA approvals and rare disease initiatives support growth.
Asia-Pacific
• Fastest-growing region, with projected CAGR above 18%.
• China, Japan, and South Korea are investing heavily in RNA biotech firms and manufacturing capacity.
• Rising prevalence of genetic and infectious diseases drives adoption.
Middle East & Africa
• Early adoption stage, but partnerships with global pharmaceutical firms are expanding access.
• Focus on infectious disease research and increasing government healthcare investments.
Latin America
• Brazil and Mexico lead the region, supported by growing clinical trial activity.
• Adoption remains moderate but is improving with regional R&D collaborations.
Regional Summary:
North America and Europe currently dominate, but Asia-Pacific is projected to be the fastest-growing market by 2034, fueled by biotech innovation, rising patient demand, and expanding infrastructure.
Market Dynamics
Growth Drivers
• Expanding Clinical Pipeline: Multiple RNA-based drugs in late-stage development.
• Unmet Medical Needs: Rare and genetic disorders driving demand for targeted therapies.
• Technological Advances: Enhanced delivery systems improving safety and efficacy.
• Investor & Government Support: Large-scale funding fueling R&D and commercialization.
Key Challenges
• Delivery Barriers: Achieving precise and safe RNA delivery remains a hurdle.
• High Costs: Complex manufacturing processes limit affordability.
• Regulatory Complexity: Global variations in approval pathways can delay commercialization.
• Safety Concerns: Potential immune activation and off-target effects.
Latest Trends
• Personalized RNA Medicine: Therapies tailored to individual patient genetic profiles.
• Combination Therapies: Pairing RNA drugs with immunotherapies or small molecules.
• Digital Biotech Partnerships: AI-driven platforms aiding RNA drug discovery.
• Expansion Beyond Rare Diseases: Growing focus on mainstream disorders like cardiovascular and oncology.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72683
Competitive Landscape
Key Players
• Alnylam Pharmaceuticals
• Ionis Pharmaceuticals
• Moderna, Inc.
• BioNTech SE
• Sarepta Therapeutics
• Wave Life Sciences
• Arrowhead Pharmaceuticals
• Arbutus Biopharma
• Silence Therapeutics
• Dicerna Pharmaceuticals (Novo Nordisk)
• GSK plc
• AstraZeneca
• Roche Holding AG
• Pfizer Inc.
• Takeda Pharmaceutical Company
Competitive Summary:
The market is led by innovators like Alnylam and Ionis in RNAi and ASOs, and Moderna and BioNTech in mRNA therapeutics. Pharma giants including Roche, AstraZeneca, and Pfizer are entering through partnerships and acquisitions. Emerging biotechs are advancing specialized pipelines for rare and neurological diseases. Intense competition and collaboration define this rapidly evolving market.
Conclusion
The RNA-Targeted Therapeutics Market is projected to expand from USD 14.7 billion in 2024 to USD 68.5 billion by 2034, at a robust CAGR of 16.4%. Fueled by the success of RNA technologies, growing clinical pipelines, and expanding delivery innovations, the market is poised to reshape drug development.
North America and Europe currently lead, but Asia-Pacific will be the fastest-growing hub, supported by significant investment, a large patient pool, and government support.
Despite challenges in delivery, cost, and regulation, RNA therapeutics represent a transformational shift in how diseases are treated - from rare genetic disorders to widespread conditions like cancer and cardiovascular diseases.
For pharmaceutical firms, biotech innovators, and investors, this decade presents an unprecedented opportunity to harness RNA therapeutics and redefine the future of precision medicine.
This report is also available in the following languages : Japanese (RNA標的治療薬市場), Korean (RNA 표적 치료제 시장), Chinese (RNA靶向治疗市场), French (Marché des thérapies ciblées par ARN), German (Markt für zielgerichtete RNA-Therapeutika), and Italian (Mercato delle terapie mirate all'RNA), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72683/rna-targeted-therapeutics-market#request-a-sample
Our More Reports:
Botanicals Market
https://exactitudeconsultancy.com/reports/73510/botanicals-market
Viral Sensitizers Market
https://exactitudeconsultancy.com/reports/73511/viral-sensitizers-market
Chromatography Market
https://exactitudeconsultancy.com/reports/73512/chromatography-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alnylam and Ionis Pharmaceuticals are the leading companies in the RNA-targeted therapeutics market, which is expected to reach USD 68.5 billion by 2034 here
News-ID: 4204231 • Views: …
More Releases from Exactitude Consultancy
Glycan Analysis Market to Reach USD 1.36 Billion by 2034, Growing at 9.8% CAGR
Introduction
Glycan analysis is a critical tool in biotechnology and pharmaceuticals, enabling detailed study of carbohydrate structures (glycans) that play vital roles in protein folding, stability, and cell signaling. Glycans are central to understanding disease mechanisms, developing biologics, and ensuring product safety and efficacy in biopharmaceutical manufacturing.
With the rise of monoclonal antibodies, biosimilars, vaccines, and cell & gene therapies, glycan profiling has become indispensable for quality control, biomarker discovery, and therapeutic…
Lipid CMO Market to Reach USD 4.9 Billion by 2034, Growing at 15.0% CAGR
Introduction
Lipids have become a critical component of modern pharmaceutical and biotechnology development, particularly as delivery systems for vaccines, nucleic acid therapies, and innovative biologics. The success of lipid nanoparticles (LNPs) in delivering mRNA COVID-19 vaccines has accelerated global demand for lipid manufacturing expertise, positioning Contract Manufacturing Organizations (CMOs) as essential partners for pharma and biotech firms.
The lipid CMO market is expanding rapidly, supported by increasing investment in gene therapies, RNA-based…
HER2 therapy market is expected to grow to $33.7 billion by 2034. Crucial Partic …
Breast cancer remains one of the most common cancers worldwide, and approximately 15-20% of breast cancers are driven by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This condition is more aggressive than HER2-negative cancers but has become highly treatable due to the development of targeted therapies. Beyond breast cancer, HER2 overexpression is also seen in gastric, colorectal, and lung cancers, making HER2 therapies an essential…
Amnesia Market to Reach USD 8.9 Billion by 2034, Expanding Growing at 6.6% CAGR
Introduction
Amnesia, characterized by partial or complete memory loss, can result from brain injury, stroke, dementia, psychological trauma, substance abuse, or neurodegenerative diseases such as Alzheimer's. While traditionally associated with aging, amnesia is increasingly recognized across all age groups due to traumatic brain injuries, mental health disorders, and substance-related complications.
Growing awareness of neurological health, advances in neuroimaging, and the rise of cognitive rehabilitation therapies are driving innovation in this space. Pharmaceutical…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
